Lamotrigine (All indications)

Learning disorders

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15249
R62696		 Ren (Lamotrigine) (Mixed indications), 2023 Danish at 9th grade - Mean age 16.1 (SD 0.4) years during pregnancy (anytime or not specified) population based cohort propective unexposed (general population or NOS) Adjustment: Yes extrapolated (cont. endpoint) 0.91 [0.74;1.13] -/192   -/370,569 - 192
ref
S8941
R30224		 Cohen-Israel (Lamotrigine), 2018 Learning disabilities (a majority between 6-12 years old) 1st trimester retrospective cohort unexposed, disease free Adjustment: No Matched 1.27 [0.33;4.89] C 5/83   4/83 9 83
ref
Total 2 studies 0.92 [0.74;1.13] 9 275
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Ren (Lamotrigine) (Mixed indications), 2023Ren, 2023 1 0.91[0.74; 1.13]-19298%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Cohen-Israel (Lamotrigine), 2018Cohen-Israel, 2018 2 1.27[0.33; 4.89]9832%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Total (2 studies) I2 = 0% 0.92[0.74; 1.13]92750.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Mixed indications; 2: Lamotrigine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.92[0.74; 1.13]92750%NARen (Lamotrigine) (Mixed indications), 2023 Cohen-Israel (Lamotrigine), 2018 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.92[0.74; 1.13]92750%NARen (Lamotrigine) (Mixed indications), 2023 Cohen-Israel (Lamotrigine), 2018 2 Tags Adjustment   - No  - No 1.27[0.33; 4.89]983 -NACohen-Israel (Lamotrigine), 2018 1   - Yes  - Yes 0.91[0.74; 1.12]-192 -NARen (Lamotrigine) (Mixed indications), 2023 1 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 0.91[0.74; 1.12]-192 -NARen (Lamotrigine) (Mixed indications), 2023 1 MatchedMatched 1.27[0.33; 4.89]983 -NACohen-Israel (Lamotrigine), 2018 1 All studiesAll studies 0.92[0.74; 1.13]92750%NARen (Lamotrigine) (Mixed indications), 2023 Cohen-Israel (Lamotrigine), 2018 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.92[0.74; 1.13]92750%NARen (Lamotrigine) (Mixed indications), 2023 Cohen-Israel (Lamotrigine), 2018 20.510.01.0